Modality
Gene Editing
MOA
CAR-T BCMA
Target
TIM-3
Pathway
Cell Cycle
RA
Development Pipeline
Preclinical
Aug 2021
→ Apr 2026
PreclinicalCurrent
NCT08899157
1,865 pts·RA
2021-08→2026-04·Not yet recruiting
1,865 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-04-081w awayInterim· RA
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
Preclinical
Not yet…
Catalysts
Interim
2026-04-08 · 1w away
RA
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08899157 | Preclinical | RA | Not yet recr... | 1865 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 | |
| ACA-2691 | Acadia Pharma | Phase 3 | BCMA |